# Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in Patients With Advanced Malignant Pleural Mesothelioma

> **NCT06031636** · — · RECRUITING · sponsor: **Tianjin Medical University Second Hospital** · enrollment: 15 (estimated)

## Conditions studied

- Malignant Pleural Mesothelioma, Advanced

## Interventions

- **DRUG:** Oncolytic Adenovirus H101
- **DRUG:** Programmed death receptor-1 inhibitor

## Key facts

- **NCT ID:** NCT06031636
- **Lead sponsor:** Tianjin Medical University Second Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-20
- **Primary completion:** 2026-07-31
- **Final completion:** 2026-07-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2023-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06031636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06031636, "Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in Patients With Advanced Malignant Pleural Mesothelioma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06031636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*